Molecular dynamics simulations of asymmetric heterodimers of HER1/HER2 complexes

被引:0
|
作者
Chonticha Suwattanasophon
Napat Songtawee
Peter Wolschann
Kiattawee Choowongkomon
机构
[1] Kasertsart University,Department of Biochemistry, Faculty of Science
[2] Kasetsart University,Center for Advanced Studies in Tropical Natural Resources, National Research University
[3] Mahidol University,Kasetsart University
[4] University of Vienna,Department of Clinical Chemistry, Faculty of Medical Technology
[5] University of Vienna,Institute for Theoretical Chemistry
来源
关键词
HER family; Molecular dynamics simulation; Heterodimer; HER1; ErbB2;
D O I
暂无
中图分类号
学科分类号
摘要
The family of human epidermal growth factor receptors (HER) is involved in tumor cell growth. Homodimerization and heterodimerization of the HER family are important for activation of these receptors. The structures of homodimer conformation are well characterized, while the structures of heterodimer conformations, especially between HER1 and HER2, are not completely understood. In this study, two models of possible asymmetric HER1/HER2 kinase domains were built. Molecular dynamics simulations and molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA) methods were applied to examine the possibility of these two-heterodimer interactions. From our results, it could be concluded that the HER2 kinase domain prefers to serve as the receiver rather than the activator. Key binding residues of this dimer complex at N lobe of HER2 is ALA683 and at C lobe of HER1 are GLU914, GLU917, and ASP930. This study will be useful in allowing us to predict and be able to control activity of this enzyme in disease in the future.
引用
收藏
相关论文
共 50 条
  • [41] CLINICAL ACTIVITY OF BIBW 2992, AN IRREVERSIBLE INHIBITOR OF EGFR/HER1 AND HER2 IN ADENOCARCINOMA OF THE LUNG WITH MUTATIONS IN THE KINASE DOMAIN OF HER2NEU
    De Greve, J.
    Decoster, L.
    De Mey, J.
    In 't Veld, P.
    Geers, C.
    Taton, M.
    Shahidi, M.
    Galdermans, D.
    Teugels, E.
    Schallier, D.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S90 - S91
  • [42] Immunostaining and gene expression of epidermal growth factor receptors (HER1/HER2) in canine cutaneous squamous cell carcinoma
    Magalhaes, Paula Lima
    Nascente, Eduardo de Paula
    Faleiro, Mariana Batista Rodrigues
    Almeida, Ana Maria de Souza
    Alves, Carlos Eduardo Fonseca
    de Moura, Veridiana Maria Brianezi Dignani
    RESEARCH IN VETERINARY SCIENCE, 2024, 177
  • [43] Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
    Bergado-Baez, Gretchen
    Suarez, Narjara Gonzalez
    Garcia, Lisset Chao
    Perez-Martinez, Dayana
    Hernandez-Fernandez, Diana Rosa
    Fundora-Barrios, Talia
    Rodriguez-Alvarez, Antonio
    Diaz-Ordaz, Geidy Diana
    Lindzen, Moshit
    Yarden, Yosef
    Sanchez-Ramirez, Belinda
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [44] Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling
    Wong, Tai W.
    Lee, Francis Y.
    Yu, Chiang
    Luo, Feng R.
    Oppenheimer, Simone
    Zhang, Hongjian
    Smykla, Richard A.
    Mastalerz, Harold
    Fink, Brian E.
    Hunt, John T.
    Gavai, Ashvinikumar V.
    Vite, Gregory D.
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6186 - 6193
  • [45] Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
    Wei, Ruicheng
    Zhang, Wenli
    Yang, Futang
    Li, Qianhao
    Wang, Qingyu
    Liu, Ningshu
    Zhu, Jun
    Shan, Yongqiang
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [46] Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors
    Steffensen, Karina Dahl
    Waldstrom, Marianne
    Andersen, Rikke Fredslund
    Olsen, Dorte Aalund
    Jeppesen, Ulla
    Knudsen, Hans Jorgen
    Brandslund, Ivan
    Jakobsen, Anders
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (01) : 195 - 204
  • [47] Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates
    Lyu, Aifeng
    Fang, Lei
    Gou, Shaohua
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 87 : 631 - 642
  • [48] HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
    Li, Bob T.
    Ross, Dara S.
    Aisner, Dara L.
    Chaft, Jamie E.
    Hsu, Meier
    Kako, Severine L.
    Kris, Mark G.
    Varella-Garcia, Marileila
    Arcila, Maria E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (03) : 414 - 419
  • [49] Based on lapatinib innovative near-infrared fluorescent probes targeting HER1/HER2 for in vivo tumors imaging
    Li, Changsheng
    Lin, Qiao
    Hu, Fangrong
    Bao, Ruichu
    Cai, Huiming
    Gu, Yueqing
    BIOSENSORS & BIOELECTRONICS, 2022, 214
  • [50] HER2、HER1在非小细胞肺癌中过度表达及其临床意义
    吴曙华
    蒋绍庆
    段光军
    胡筠珠
    胡华成
    肿瘤, 2005, (05) : 60 - 63